Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00075816
Recruitment Status : Completed
First Posted : January 13, 2004
Results First Posted : February 1, 2016
Last Update Posted : January 4, 2023
National Heart, Lung, and Blood Institute (NHLBI)
Blood and Marrow Transplant Clinical Trials Network
National Cancer Institute (NCI)
National Marrow Donor Program
Information provided by (Responsible Party):
Medical College of Wisconsin

Brief Summary:
The study is designed as a Phase III, randomized, open label, multicenter, prospective, comparative trial of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC) versus marrow from unrelated donors for transplantation in patients with hematologic malignancies. Recipients will be stratified by transplant center and disease risk and will be randomized to either the PBSC or marrow arm in a 1:1 ratio.

Condition or disease Intervention/treatment Phase
Leukemia Myeloproliferative Disorders Myelodysplastic-Myeloproliferative Diseases Biological: Allogeneic bone marrow transplantation Biological: Peripheral blood stem cell transplantation Phase 3

Detailed Description:


Many studies of allogeneic marrow transplantation have shown that a higher dose of marrow cells correlates with more robust hematopoietic engraftment and lower mortality from infectious complications. Peripheral blood stem cells (PBSC) collected after mobilization with granulocyte colony stimulating factor (G-CSF) contain a larger number of CD34-positive (CD34) progenitors and total cells than bone marrow. These observations led to the hypothesis that transplantation of PBSC would lead to lower mortality compared to transplantation of marrow. In addition, PBSC grafts have a higher T cell content, predicting a possibly more powerful anti-leukemia effect. However, the higher T cell content of PBSC may also lead to increased incidence and severity of acute and chronic graft-versus-host disease (GVHD). This concern is especially serious when the donor is unrelated to the recipient. This prospective, randomized, multicenter clinical trial of unrelated donor transplantation will test the hypothesis that transplantation of PBSC leads to similar patient survival compared to transplantation of marrow.


This is a Phase III randomized, open label, multicenter clinical trial sponsored by the National Marrow Donor Program (NMDP) and the National Institutes of Health (NIH). The objective of the trial is to test the null hypothesis that there is no difference in overall survival after PBSC versus marrow transplants from HLA compatible unrelated donors. The study will compare G-CSF-mobilized PBSC transplantation with bone marrow transplantation from HLA-compatible unrelated donors for patients with leukemia, myelodysplastic or myeloproliferative syndromes. Conditioning and GVHD prophylaxis regimens will vary by center and within centers, however, the center must declare before randomization what regimens will be used for each patient. The primary endpoint of this trial is 2-year survival following randomization. Secondary analyses will consider neutrophil and platelet recovery, acute and chronic GVHD, time off all immunosuppressive therapy, relapse, infections, adverse events and immune reconstitution. The trial will include evaluation of patient and donor quality of life, composition of the graft, and immune reconstitution. Accrual is anticipated for 3 years with a follow-up period of 3 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 551 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Study Start Date : January 2004
Actual Primary Completion Date : April 2013
Actual Study Completion Date : April 2014

Arm Intervention/treatment
Active Comparator: Bone Marrow Transplant
Allogeneic bone marrow transplantation
Biological: Allogeneic bone marrow transplantation
Bone marrow transplant from HLA compatible unrelated donors.

Active Comparator: Blood Stem Cell Transplant
Peripheral blood stem cell transplantation
Biological: Peripheral blood stem cell transplantation
Peripheral blood transplant from HLA compatible unrelated donors.

Primary Outcome Measures :
  1. Two-year Overall Survival [ Time Frame: Measured at 2 years ]
    Overall survival rate at 2 years according to an intention-to-treat analysis.

Secondary Outcome Measures :
  1. Neutrophil Engraftment [ Time Frame: Measured at Day 28 ]
  2. Platelet Engraftment [ Time Frame: Measured at Day 180 ]
  3. Graft Failure [ Time Frame: Measured at 28 and 100 days ]
  4. Extensive Chronic Graft-versus-host Disease (GVHD) [ Time Frame: Measured at 730 days ]
  5. Chronic GVHD [ Time Frame: Measured at 2 years ]
  6. Relapse [ Time Frame: Measured at 2 years ]
    Analysis restricted to patients who received the transplant.

  7. Infections [ Time Frame: Measured at 1 and 2 years ]
    Number of infection reports per patient.

  8. Grades III-V Unexpected Adverse Events [ Time Frame: Measured by 2 years ]
  9. Acute GVHD Grade II-IV [ Time Frame: 100 days, 180 days ]
  10. Acute GVHD Grade III-IV [ Time Frame: 100 days, 180 days ]
  11. Current Immunosuppressive (IS) Free Survival [ Time Frame: Measured at 2 years ]
    This outcome measure takes into account subsequent immunosuppressive therapy that may occur following discontinuation of initial immunosuppressive therapy.

  12. Immune Reconstitution [ Time Frame: Measured at 100 days, 6 months, and 1 and 2 years ]
  13. Donor Recovery of Baseline Complete Blood Count (CBC) and White Blood Cell Count (WBC) Differential [ Time Frame: Measured at 1, 6, and 12 months ]
  14. Donor Recovery to Baseline Toxicity Scores [ Time Frame: Measured at 1, 6, and 12 months ]
  15. Donor Quality of Life [ Time Frame: Measured at 1, 6, and 12 months ]
  16. Patient Quality of Life [ Time Frame: Measured at baseline, 6 months, and 1, 2, and 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 66 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Patient Inclusion Criteria:

One of the following diagnoses:

  • Acute myelogenous leukemia at the following stages: first remission, second remission, third or subsequent remission, or not in remission
  • Acute lymphoblastic leukemia at the following stages: first remission, second remission, third or subsequent remission, or not in remission
  • Chronic myelogenous leukemia at the following stages: chronic phase, accelerated phase, or blast phase
  • Myelodysplastic syndromes (MDS) at the following stages: refractory anemia; refractory anemia with ringed sideroblasts; refractory cytopenia with multilineage dysplasia; refractory cytopenia with multilineage dysplasia and ringed sideroblasts; refractory anemia with excess blasts-1 (5-10% blasts); refractory anemia with excess blasts-2 (10-20% blasts); myelodysplastic syndrome, unclassified; or MDS associated with isolated del (5q)
  • Myeloproliferative diseases: chronic myelomonocytic leukemia; agnogenic myeloid metaplasia with myelofibrosis (idiopathic myelofibrosis); juvenile myelomonocytic leukemia
  • Therapy-related acute myelogenous leukemia (AML) or MDS with prior malignancy that has been in remission for at least 12 months. If the remission is less than 12 months, Medical Monitor or Protocol Chair approval is required for eligibility

Patient Exclusion Criteria:

  • Prior allogeneic or autologous transplants using any hematopoietic stem cell source; patients with secondary malignancies who have had a prior autologous transplant will be eligible; the prior autologous transplant must have been performed for the primary malignancy (such as lymphoma) and must have occurred 12 or more months prior to enrollment
  • Lymphoma (11% of 2001 NMDP transplants), other malignant disorders (6%), and non-malignant disorders (9%)

Donor Inclusion Criteria:

  • Matched for HLA-A, B, and DRB1 antigens

    1. One antigen mismatch at HLA-A, B, or DRB1 is acceptable with or without mismatch at HLA-C
    2. Typing is by DNA techniques: intermediate resolution for A, B, and C, and high resolution for DRB1. HLA-C typing is mandatory but will not count in the match.
  • Willing to undergo both bone marrow harvest and G-CSF administration with apheresis
  • Willing to be randomly assigned to either marrow or PBSC collection
  • Adequate peripheral venous access for leukapheresis or willing to undergo placement of a central catheter
  • Donor center affiliation with NMDP
  • Additional donor inclusion criteria can be found in the Donor Companion Manual

Donor Exclusion Criteria:

  • Pregnant (positive serum β-HCG) or uninterruptible breastfeeding
  • Known allergy to G-CSF or to E. Coli-derived recombinant protein products
  • History of autoimmune disorders
  • History of deep vein thrombosis or venous thromboembolism
  • History of iritis or episcleritis
  • History of serious adverse reaction to anesthesia
  • Thrombocytopenia (platelets less than 150,000 per mcL) at baseline evaluation
  • Current treatment with lithium
  • Presence of sickle hemoglobin as demonstrated by appropriate testing such as hemoglobin electrophoresis
  • Receiving experimental therapy or investigational agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00075816

Show Show 45 study locations
Sponsors and Collaborators
Medical College of Wisconsin
National Heart, Lung, and Blood Institute (NHLBI)
Blood and Marrow Transplant Clinical Trials Network
National Cancer Institute (NCI)
National Marrow Donor Program
Layout table for investigator information
Study Director: Mary Horowitz, MD Center for International Blood and Marrow Transplant Research
  Study Documents (Full-Text)

Documents provided by Medical College of Wisconsin:
Additional Information:
Publications of Results:

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medical College of Wisconsin Identifier: NCT00075816    
Obsolete Identifiers: NCT00321776, NCT00473395
Other Study ID Numbers: BMTCTN0201
U01HL069294-05 ( U.S. NIH Grant/Contract )
BMT CTN 0201 ( Other Identifier: Blood and Marrow Transplant Clinical Trials Network )
5U24CA076518 ( U.S. NIH Grant/Contract )
First Posted: January 13, 2004    Key Record Dates
Results First Posted: February 1, 2016
Last Update Posted: January 4, 2023
Last Verified: December 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Results will be published in a manuscript
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Time Frame: Within 6 months of official study closure at participating sites.
Access Criteria: Available to the public
Additional relevant MeSH terms:
Layout table for MeSH terms
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Bone Marrow Diseases
Hematologic Diseases